Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy

No abstract is available for this paper.

• Publication year

  1993

• Venue

  British Journal of Haematology

• Publication date

  1993-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.1993.tb04699.xPMID 8518178
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study.

  1991cited by this paper
• Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study.

  1991cited by this paper
• Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort.

  1991cited by this paper
• Antithrombin III and procoagulant activity: sex differences and effects of the menopause

  1990cited by this paper
• Menopause and risk factors for coronary heart disease.

  1990cited by this paper
• Coronary Risk Factor and Lifestyle Variation across Scotland: Results from the Scottish Heart Health Study

  1989cited by this paper
• The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women.

  1989cited by this paper
• Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study.

  1989cited by this paper
• Concomitants of Excess Coronary Deaths — Major Risk Factor and Lifestyle Findings from 10,359 Men and Women in the Scottish Heart Health Study

  1989cited by this paper
• Menopause and Risk Factors for Coronary Heart Disease

  1989cited by this paper
• Increased risk of atherosclerosis in women after the menopause.

  1989cited by this paper
• The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators.

  1988cited by this paper
• The World Health Organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collabaration

  1988cited by this paper
• The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): A major international Collaboration

  1988cited by this paper
• Benefits and risks of menopausal estrogen and/or progestin hormone use.

  1988cited by this paper
• Coagulation effects of oral contraception.

  1987cited by this paper
• Fibrinogen and risk of cardiovascular disease. The Framingham Study.

  1987cited by this paper
• Menopause and the risk of coronary heart disease in women.

  1987cited by this paper
• The Scottish Heart Health Study: objectives and development of methods.

  1987cited by this paper
• Menopause and the risk of coronary heart disease in women.

  1987cited by this paper
• Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.

  1986cited by this paper
• Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study.

  1985cited by this paper
• Oral contraception and coagulation.

  1985cited by this paper
• Effects of Oral Contraceptives on Blood Coagulation. A Review

  1985cited by this paper
• Menopausal status and haemostatic variables.

  1983cited by this paper
• Oral contraceptives and blood coagulation: a critical review.

  1982cited by this paper
• Intraindividual changes of blood pressure, serum lipids, and body weight in relation to menstrual status: results from a prospective population study of women in Göteborg, Sweden.

  1982influential reference
• Menopausal oestrogen therapy and protection from death from ischaemic heart disease.

  1981cited by this paper
• Early menopause and the risk of myocardial infarction.

  1981cited by this paper
• Increased blood viscosity in young women using oral contraceptives

  1980cited by this paper
• Menopause and Coronary Heart Disease. The Framingham Study

  1979cited by this paper
• Increased blood viscosity in young women using oral contraceptives.

  1979cited by this paper
• Oral contraceptives, blood clotting and thrombosis.

  1978cited by this paper
• An Epidemiological Study of the Haemostatic and Other Effects of Oral Contraceptives

  1976cited by this paper
• Progestational agents and blood coagulation. V. Changes induced by sequential oral contraceptive therapy.

  1974cited by this paper
• Effect of combined oestrogen-progestogen oral contraceptives, oestrogen, and progestogen on antiplasmin and antithrombin activity.

  1970cited by this paper
• THROMBOEMBOLISM AND ORAL CONTRACEPTIVES: AN EPIDEMIOLOGIC CASE-CONTROL STUDY

  1970cited by this paper
• Thromboembolism and oral contraceptives: an epidemiologic case-control study.

  1969cited by this paper
• Relation between oral contraceptive hormones and blood clotting

  1969cited by this paper
• Investigation of relation between use of oral contraceptives and thromboembolic disease.

  1968cited by this paper
• Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens

  1957cited by this paper
• [Rapid physiological coagulation method in determination of fibrinogen].

  1957cited by this paper

• Sex-specific association between microvascular health and coagulation parameters: the Netherlands Epidemiology of Obesity (NEO) Study.

  2023cites this paper
• Early cardiac change after menopause-an open level comparative study

  2021cites this paper
• Systemic inflammation and late-life cognitive ability

  2015cites this paper
• HYPERFIBRINOGENEMIA IN RELATION TO GLYCEMIC STATUS AND DYSLIPIDEMIA IN TYPE 2 DIABETES MELLITUS AND CORONARY HEART DISEASE

  2015cites this paper
• Coronary Heart Disease in Postmenopausal Women with Type II Diabetes Mellitus and the Impact of Estrogen Replacement Therapy: A Narrative Review

  2014cites this paper
• Menopause: Its Epidemiology

  2013cites this paper
• Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater

  2011cites this paper
• Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater

  2011cites this paper
• Protrhombotic effects of contraceptives.

  2010cites this paper
• Postmenopausal Hormone Therapy: : Differential Impact of Dose and Regimenson Hemostasis and Inflammation

  2009cites this paper
• The Effects of Rosiglitazone, Metformin, and Estradiol-cyproterone Acetate on Lean Patients With Polycystic Ovary Syndrome

  2009cites this paper
• Transdermal estradiol and lipid profile: effects on a specific group of Brazilian postmenopausal women.

  2009cites this paper
• Hormonal therapy and thromboembolic disease

  2008cites this paper
• Studies on subfractions of fibrinogen : With special emphasis on fibrinogen quantification, viscosity and inflammation

  2008cites this paper
• Fibrinogen: a predictor of vascular disease.

  2007cites this paper
• Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome.

  2007cites this paper
• Clinical and Research Applications of Markers of Thrombosis

  2006cites this paper
• Fibrinógeno: ¿Factor o indicador de riesgo cardiovascular?

  2006cites this paper
• Hemostatic factors and ischemic heart disease risk among postmenopausal women

  2005cites this paper
• Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women.

  2005cites this paper
• Ischemic heart disease in women and the role of hormone therapy.

  2004cites this paper
• [Hormone replacement therapy and prevention of cardiovascular diseases.].

  2004cites this paper
• Menopause, hormone replacement therapy and hemorheology

  2004cites this paper
• Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease

  2004cites this paper
• Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women.

  2004cites this paper
• Fibrinogen: biochemistry, epidemiology and determinants.

  2003cites this paper
• Tromboembolismo venoso e terapia de reposição hormonal da menopausa: uma análise clínico-epidemiológica

  2003cites this paper
• Influence of Socioeconomic Status and Job Control on Plasma Fibrinogen Responses to Acute Mental Stress

  2003cites this paper
• Increased Fibrin Polymerization Rate in Patients with Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus

  2003cites this paper
• Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women.

  2002cites this paper
• The effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta-analysis of 46 studies

  2002cites this paper
• Effect of methyl testosterone administration on plasma viscosity in postmenopausal women

  2002cites this paper
• The effect of 17β-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus

  2002cites this paper
• Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations.

  2002cites this paper
• The effect of 17 beta-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus.

  2002cites this paper
• Update on cardiovascular disease in post-menopausal women.

  2002cites this paper
• Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy.

  2001cites this paper
• Smoking, other risk factors and fibrinogen levels. evidence of effect modification.

  2001cites this paper
• Menopause and weight.

  2001cites this paper
• Fibrinogen fractions in the third trimester of pregnancy and in puerperium.

  2000cites this paper
• The Effect of Hormone Replacement Therapy and Exercise on Cardiovascular Disease Risk Factors in Postmenopausal Women

  2000cites this paper
• Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant?

  2000cites this paper
• The relationship between plasma viscosity and cholesterol in postmenopausal women on hormone replacement therapy

  2000cites this paper
• Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and bone density patterns.

  2000cites this paper
• 92 – Menopause: Its Epidemiology

  2000cites this paper
• [Modifications of the hemostatic balance during estrogen treatments: menopause and its treatment].

  1999cites this paper
• Lipoprotein(a) Levels and Isoforms and Fibrinolytic Activity in Postmenopause – Influence of Hormone Replacement Therapy

  1999cites this paper
• Effects of hormone replacement therapy on hemostatic cardiovascular risk factors.

  1999cites this paper
• Fibrinogen and women's health.

  1999cites this paper
• Associations of blood rheology and interleukin‐6 with cardiovascular risk factors and prevalent cardiovascular disease

  1999cites this paper
• Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women.

  1999cites this paper
• Use Of Fibrinogen and Fibrin D-Dimer in Prediction of Arterial Thrombotic Events

  1999cites this paper
• Antipeptide Monoclonal Antibodies to Defined Fibrinogen Aα Chain Regions: Anti-Aα 487-498, a Structural Probe for Fibrinogenolysis

  1998cites this paper
• Antipeptide monoclonal antibodies to defined fibrinogen Aalpha chain regions: anti-Aalpha 487-498, a structural probe for fibrinogenolysis.

  1998cites this paper
• Cardiorespiratory fitness and cardiovascular disease risk factors in postmenopausal women.

  1998cites this paper
• β-Fibrinogen Gene Polymorphism (C148→T) Is Associated With Carotid Atherosclerosis

  1998cites this paper
• Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study.

  1998cites this paper
• Beta-fibrinogen gene polymorphism (C148-->T) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study.

  1998cites this paper
• Hormone replacement therapy: cardiovascular benefits for aging women.

  1998cites this paper
• Oral contraceptives and oestrogen replacement therapy as determinants of plasma fibrinogen level and fibrinolytic activity the northern sweden MONICA study

  1998cites this paper
• Parity, Postmenopausal Estrogen Use, and Cardiovascular Disease Risk Factors in American Indian Women: The Strong Heart Study

  1997cites this paper
• Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study

  1997cites this paper
• EPIDEMIOLOGY OF COAGULATION FACTORS, INHIBITORS AND ACTIVATION MARKERS: THE THIRD GLASGOW MONICA SURVEY I. ILLUSTRATIVE REFERENCE RANGES BY AGE, SEX AND HORMONE USE

  1997cites this paper
• Issues concerning androgen replacement therapy in postmenopausal women.

  1997cites this paper
• Fibrinogen and plasminogen modifications during oral estradiol replacement therapy.

  1997cites this paper
• Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

  1997cites this paper
• Veränderungen hämostaseologischer Parameter unter Hormonsubstitutionstherapie in Abhängigkeit von der Gestagendosis

  1997cites this paper
• Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease

  1997cites this paper
• Effects of androgens on haemostasis

  1996cites this paper
• [Fibrinogen: a risk factor].

  1996cites this paper
• Effects of androgens on haemostasis.

  1996cites this paper
• Perimenopausal and postmenopausal hormone replacement therapy. Part 1. An update of the literature on benefits and risks.

  1996cites this paper
• ALTERATIONS IN PLASMA FIBRINOGEN DURING LIFE EVENTS IN WOMEN

  1996cites this paper
• Menopause and risk of cardiovascular disease.

  1996cites this paper
• Thrombophilia and lipid profile in post-menopausal women using a new transdermal oestradiol patch.

  1996cites this paper
• Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women.

  1996cites this paper
• Kardiovaskuläre Erkrankungen und Hormonsubstitution in der Menopause

  1996cites this paper
• Plasma Fibrinogen Levels and Their Association to Life Styles in the Rural Japanese Population

  1995cites this paper
• Menopause: its epidemiology and potential association with chronic diseases.

  1995cites this paper
• Genetic regulation of fibrinogen.

  1995cites this paper
• Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. The FINRISK Hemostasis Study.

  1995cites this paper
• The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status.

  1995cites this paper
• Fibrinogen and Cardiovascular Risk

  1995cites this paper
• Effect of a new cyclical sequential postmenopausal HRT on lipoprotein, apoprotein and thrombophilia profile.

  1995cites this paper
• Diet, blood coagulation and fibrinolysis.

  1995cites this paper
• The effects of two phasic oral contraceptives on hemostasis and platelet function

  1995cites this paper
• Fibrinogen, arterial risk factor, in clinical practice

  1994cites this paper
• Transdermal Estradiol/Norethisterone

  1994cites this paper
• Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.

  1994cites this paper
• Menopause LiteratureWatch

  1994cites this paper
• Routine measurement of fibrinogen concentration.

  1993cites this paper